839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial
Lixin Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Junying Xu(Wuxi People's Hospital), Hongwei Ling, Zhifeng Cheng(Harbin Medical University), Lili Zhang(Northeast Forestry University), XIAOXIA SHI, Junhua Song(Washington State University), SHUGUANG PANG, Liping Zhong(Guangxi Medical University), Hong Gao(Shanghai Jiao Tong University), Xin Wang(Hong Kong University of Science and Technology), Lijun Shen(Wenzhou Medical University)
Cited by 0
Related Papers
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors
|Nature|2011|860
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2022|191
Engineering a precise adenine base editor with minimal bystander editing
|Nature Chemical Biology|2022|183